Activity of FB2, a novel dual Abl/Src tyrosine kinase inhibitor, against imatinib-resistant chronic myeloid leukemia in vivo and in vitro

References

• Rowley J D. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290–293
   PubMed Web of Science ®Google Scholar
• de Klein A, van Kessel A G, Grosveld G, Bartram C R, Hagemeijer A, Bootsma D, et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982; 300: 765–767
   PubMed Web of Science ®Google Scholar
• Buchdunger E, Matter A, Druker B J. Bcr-Abl inhibition as a modality of CML therapeutics. Biochim Biophys Acta 2001; 1551: M11–M18
   PubMed Web of Science ®Google Scholar
• Hegedus T, Orfi L, Seprodi A, Varadi A, Sarkadi B, Keri G. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim Biophys Acta 2002; 1587: 318–325
   PubMed Web of Science ®Google Scholar
• Gorre M E, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao P N, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–880
   PubMed Web of Science ®Google Scholar
• Hofmann W K, Jones L C, Lemp N A, de Vos S, Gschaidmeier H, Hoelzer D, et al. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 2002; 99: 1860–1862
   PubMed Web of Science ®Google Scholar
• Nardi V, Azam M, Daley G Q. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol 2004; 11: 35–43
   PubMed Web of Science ®Google Scholar
• Deininger M W, Holyoake T L. Can we afford to let sleeping dogs lie?. Blood 2005; 105: 1840–1841
   PubMed Web of Science ®Google Scholar
• Donato N J, Wu J Y, Stapley J, Gallick G, Lin H, Arlinghaus R, et al. BCR-ABL independence and LYN kinase over expression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101: 690–698
   PubMed Web of Science ®Google Scholar
• Dai Y, Rahmani M, Corey S J, Dent P, Grant S. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 2004; 279: 34227–34239
   PubMed Web of Science ®Google Scholar
• Cowan-Jacob S W, Guez V, Fendrich G, Griffin J D, Fabbro D, Furet P, et al. Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev Med Chem 2004; 4: 285–299
   PubMed Web of Science ®Google Scholar
• Tokarski J S, Newitt J A, Chang C Y, Cheng J D, Wittekind M, Kiefer S E, et al. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006; 66: 5790–5797
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Gasser M, Ahmed S, Assouline S, Scapozza L. Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies. Leukemia 2005; 19: 1267–1269
   PubMed Web of Science ®Google Scholar
• Nam S, Kim D, Cheng J Q, Zhang S, Lee J H, Buettner R, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005; 65: 9185–9189
   PubMed Web of Science ®Google Scholar
• Chen Z, Lee F Y, Bhalla K N, Wu J. Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol 2006; 69: 1527–1533
   PubMed Web of Science ®Google Scholar
• Qi J, Peng H, Gu Z L, Liang Z Q, Yang C Z. Establishment of an imatinib resistant cell line K562/G01 and its characterization. Zhonghua Xue Ye Xue Za Zhi 2004; 25: 337–341
   PubMedGoogle Scholar
• Tringali C, Lupo B, Anastasia L, Papini N, Monti E, Bresciani R, et al. Expression of sialidase Neu2 in leukemic K562 cells induces apoptosis by impairing Bcr-Abl/Src kinases signaling. J Biol Chem 2007; 282: 14364–14372
   PubMed Web of Science ®Google Scholar
• Johnson J I, Decker S, Zaharevitz D, Rubinstein L V, Venditti J M, Schepartz S, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001; 84: 1424–1431
   PubMed Web of Science ®Google Scholar
• Borowski E, Bontemps-Gracz M M, Piwkowska A. Strategies for overcoming ABC-transporters-mediated multidrug resistance (MDR) of tumor cells. Acta Biochim Pol 2005; 52: 609–627
   PubMed Web of Science ®Google Scholar
• Gottesman M M. Mechanisms of cancer drug resistance. Annu Rev Med 2002; 53: 615–627
   PubMed Web of Science ®Google Scholar
• Endicott J A, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989; 58: 137–171
   PubMed Web of Science ®Google Scholar
• Marie J P, Faussat-Suberville A M, Zhou D, Zittoun R. Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression. Leukemia 1993; 7: 825–831
   PubMed Web of Science ®Google Scholar
• Shah N P, Nicoll J M, Nagar B, Gorre M E, Paquette R L, Kuriyan J, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117–125
   PubMed Web of Science ®Google Scholar
• le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000; 95: 1758–1766
   PubMed Web of Science ®Google Scholar
• Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette P K, Loughran T, et al. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2002; 62: 5761–5769
   PubMed Web of Science ®Google Scholar
• Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker B J, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56: 100–104
   PubMed Web of Science ®Google Scholar
• Buchdunger E, Cioffi C L, Law N, Stover D, Ohno-Jones S, Druker B J, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139–145
   PubMed Web of Science ®Google Scholar
• Druker B J, Tamura S, Buchdunger E, Ohno S, Segal G M, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561–566
   PubMed Web of Science ®Google Scholar
• Demetri G D. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). Eur J Cancer 2002; 38(Suppl. 5)S52–S59
   PubMed Web of Science ®Google Scholar
• Donato N J, Wu J Y, Stapley J, Lin H, Arlinghaus R, Aggarwal B B, et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004; 64: 672–677
   PubMed Web of Science ®Google Scholar
• Danhauser-Riedl S, Warmuth M, Druker B J, Emmerich B, Hallek M. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res 1996; 56: 3589–3596
   PubMed Web of Science ®Google Scholar
• Lombardo L J, Lee F Y, Chen P, Norris D, Barrish J C, Behnia K, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658–6661
   PubMed Web of Science ®Google Scholar
• Warmuth M, Bergmann M, Priess A, Hauslmann K, Emmerich B, Hallek M. The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr. J Biol Chem 1997; 272: 33260–33270
   PubMed Web of Science ®Google Scholar
• Klejman A, Schreiner S J, Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall T E, et al. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J 2002; 21: 5766–5774
   PubMed Web of Science ®Google Scholar
• Stanglmaier M, Warmuth M, Kleinlein I, Reis S, Hallek M. The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains. Leukemia 2003; 17: 283–289
   PubMed Web of Science ®Google Scholar
• Lionberger J M, Wilson M B, Smithgall T E. Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. J Biol Chem 2000; 275: 18581–18585
   PubMed Web of Science ®Google Scholar
• Wilson M B, Schreiner S J, Choi H J, Kamens J, Smithgall T E. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene 2002; 21: 8075–8088
   PubMed Web of Science ®Google Scholar
• Warmuth M, Simon N, Mitina O, Mathes R, Fabbro D, Manley P W, et al. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood 2003; 101: 664–672
   PubMed Web of Science ®Google Scholar
• Chang Y M, Kung H J, Evans C P. Nonreceptor tyrosine kinases in prostate cancer. Neoplasia 2007; 9: 90–100
   PubMed Web of Science ®Google Scholar
• Fizazi K. The role of Src in prostate cancer. Ann Oncol 2007; 18: 1765–1773
   PubMed Web of Science ®Google Scholar
• Hiscox S, Morgan L, Green T, Nicholson R I. Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. Endocr Relat Cancer 2006; 13(Suppl. 1)S53–S59
   PubMed Web of Science ®Google Scholar
• Jackson J G, Yoneda T, Clark G M, Yee D. Elevated levels of p66 Shc are found in breast cancer cell lines and primary tumors with high metastatic potential. Clin Cancer Res 2000; 6: 1135–1139
   PubMed Web of Science ®Google Scholar
• Slack J K, Adams R B, Rovin J D, Bissonette E A, Stoker C E, Parsons J T. Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells. Oncogene 2001; 20: 1152–1163
   PubMed Web of Science ®Google Scholar